SCHEMBL6574587

SCHEMBL6574587

Cc1ccnc(Br)c1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2483892 0.75
SCHEMBL30105439 0.75
SCHEMBL29843421 0.75
SCHEMBL1128280 0.75
SCHEMBL1461333 0.75
SCHEMBL29490275 0.75
SCHEMBL3015741 0.75
SCHEMBL5582899 0.75
SCHEMBL316298 0.73
Ammonia Solution, Strong SCHEMBL27929396 0.73 NOS2 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035379-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-02-05 US disclosed
US-12534475-B2 Bicyclic pyridine derivative Sumitomo Pharma Co., Ltd. (JP) 2026-01-27 US disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-12077546-B2 Bicyclic pyridine derivative Sumitomo Pharma Co., Ltd. (JP) 2024-09-03 US disclosed
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-07-11 US disclosed
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-05-09 US disclosed
EP-4324834-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-02-21 EP disclosed
CN-117177977-A Bicyclic pyridine derivatives 住友制药株式会社 2023-12-05 CN disclosed
WO-2022215754-A1 BICYCLIC PYRIDINE DERIVATIVE 住友ファーマ株式会社 2022-10-13 WO disclosed
US-10392397-B2 Heterocyclic thiosemicarbazone derivatives and their therapeutical applications NANTBIO, INC. (US) 2019-08-27 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
EP-1442036-A2 HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 SCHERING CORPORATION (US) 2004-08-04 EP disclosed
US-6727254-B2 8-(BIS-(PHENYL) METHYL)-3-HETEROARYL-8-AZABICYCLO-(3.2.1)OCTAN-3-OLS AND DERIVATIVES, USEFUL IN TREATING PAIN, ANXIETY, COUGH, ASTHMA, DEPRESION AND ALCOHOL ABUSE SCHERING CORPORATION 2004-04-27 US disclosed
US-20030119847-A1 Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 SCHERING CORPORATION 2003-06-26 US disclosed
WO-2003039469-A2 HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 SCHERING CORPORATION (US) 2003-05-15 WO disclosed